Kenneth A Getz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7452849/publications.pdf

Version: 2024-02-01

61	2,169	430754	233338
papers	citations	18 h-index	45 g-index

63	63	63	2615
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Central Challenges Facing the National Clinical Research Enterprise. JAMA - Journal of the American Medical Association, 2003, 289, 1278.	3.8	1,052
2	Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances. JAMA - Journal of the American Medical Association, 2021, 326, 257.	3.8	168
3	Assessing the Impact of Protocol Design Changes on Clinical Trial Performance. American Journal of Therapeutics, 2008, 15, 450-457.	0.5	123
4	Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTIâ€™s Patient Groups and Clinical Trials Project. Therapeutic Innovation and Regulatory Science, 2018, 52, 220-229.	0.8	96
5	Global Public Attitudes About Clinical Research and Patient Experiences With Clinical Trials. JAMA Network Open, 2018, 1, e182969.	2.8	67
6	Measuring the Incidence, Causes, and Repercussions of Protocol Amendments. Drug Information Journal, 2011, 45, 265-275.	0.5	48
7	Racial Disparities Among Clinical Research Investigators. American Journal of Therapeutics, 2008, 15, 3-11.	0.5	46
8	A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals. Drug Safety, 2016, 39, 1117-1127.	1.4	39
9	The Impact of Protocol Amendments on Clinical Trial Performance and Cost. Therapeutic Innovation and Regulatory Science, 2016, 50, 436-441.	0.8	37
10	Improving Protocol Design Feasibility to Drive Drug Development Economics and Performance. International Journal of Environmental Research and Public Health, 2014, 11, 5069-5080.	1.2	36
11	Evaluating the Completeness and Accuracy of MedWatch Data. American Journal of Therapeutics, 2014, 21, 442-446.	0.5	34
12	Quantifying the Magnitude and Cost of Collecting Extraneous Protocol Data. American Journal of Therapeutics, 2015, 22, 117-124.	0.5	32
13	New Benchmarks Characterizing Growth in Protocol Design Complexity. Therapeutic Innovation and Regulatory Science, 2018, 52, 22-28.	0.8	31
14	Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. Therapeutic Innovation and Regulatory Science, 2020, 54, 103-116.	0.8	30
15	Variability in Protocol Design Complexity by Phase and Therapeutic Area. Drug Information Journal, 2011, 45, 413-420.	0.5	25
16	Examining and Enabling the Role of Health Care Providers as Patient Engagement Facilitators in Clinical Trials. Clinical Therapeutics, 2017, 39, 2203-2213.	1.1	25
17	Evaluating the Completeness of ClinicalTrials.gov. Therapeutic Innovation and Regulatory Science, 2019, 53, 307-317.	0.8	22
18	Establishing Return-on-Investment Expectations for Patient-Centric Initiatives. Therapeutic Innovation and Regulatory Science, 2015, 49, 745-749.	0.8	20

#	Article	IF	Citations
19	Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. Therapeutic Innovation and Regulatory Science, 0, , 216847901881751.	0.8	20
20	Meeting the obligation to communicate clinical trial results to study volunteers. Expert Review of Clinical Pharmacology, 2012, 5, 149-156.	1.3	19
21	Open innovation: the new face of pharmaceutical research and development. Expert Review of Clinical Pharmacology, 2012, 5, 481-483.	1.3	19
22	Reflections on the Evolution of Patient Engagement in Drug Development. Pharmaceutical Medicine, 2019, 33, 179-185.	1.0	15
23	The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times. Therapeutic Innovation and Regulatory Science, 2014, 48, 482-487.	0.8	14
24	Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. Clinical Infectious Diseases, 2018, 66, 72-80.	2.9	13
25	Taking the Pulse of Strategic Outsourcing Relationships. Clinical Therapeutics, 2014, 36, 1349-1355.	1.1	11
26	Assessing Patient Participation Burden Based on Protocol Design Characteristics. Therapeutic Innovation and Regulatory Science, 2019, , 216847901986728.	0.8	11
27	New Governance Mechanisms to Optimize Protocol Design. Therapeutic Innovation and Regulatory Science, 2013, 47, 651-655.	0.8	9
28	Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient. Clinical Therapeutics, 2020, 42, e150-e159.	1.1	9
29	Quantifying Patient Subpopulation Disparities in New Drugs and Biologics Approved Between 2007 and 2017. Therapeutic Innovation and Regulatory Science, 2020, 54, 1541-1550.	0.8	8
30	Global Investigative Site Personnel Diversity and Its Relationship with Study Participant Diversity. Therapeutic Innovation and Regulatory Science, 2022, 56, 777-784.	0.8	8
31	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. Lupus Science and Medicine, 2021, 8, e000433.	1.1	7
32	Generational Value Differences Affecting Public Perceptions of and Willingness to Participate in Clinical Trials. Therapeutic Innovation and Regulatory Science, 2015, 49, 940-946.	0.8	6
33	Baseline Assessment of a Global Clinical Investigator Landscape Poised for Structural Change. Therapeutic Innovation and Regulatory Science, 2017, 51, 575-581.	0.8	5
34	The Expanding Outside Clinical Services Contractor Marketplace. Clinical Research and Regulatory Affairs, 1997, 14, 191-204.	2.1	4
35	Drug development study designs have reached the danger zone. Expert Review of Clinical Pharmacology, 2013, 6, 589-591.	1.3	4
36	Protocol Design Variables Highly Correlated with, and Predictive of, Clinical Trial Performance. Therapeutic Innovation and Regulatory Science, 2022, 56, 333-345.	0.8	4

#	Article	IF	Citations
37	Quantifying Diversity and Representation in Pivotal Trials Leading to Marketing Authorization in Europe. Therapeutic Innovation and Regulatory Science, 2022, 56, 795-804.	0.8	4
38	Factors Influencing Investigative Site Willingness and Ability to Participate in Clinical Trials. Drug Information Journal, 2011, 45, 377-390.	0.5	3
39	Impact of In-Pharmacy Education on Patientsâ€™ Knowledge and Attitudes About Clinical Trials. Therapeutic Innovation and Regulatory Science, 2013, 47, 336-340.	0.8	3
40	Therapeutic area variability in the collection of data supporting protocol end points and objectives. Clinical Investigation, 2014, 4, 125-130.	0.0	3
41	Assessing the Scope and Predictors of Intentional Dose Non-adherence in Clinical Trials. Therapeutic Innovation and Regulatory Science, 2020, 54, 1330-1338.	0.8	3
42	Assessing Patient Participation Burden Based on Protocol Design Characteristics. Therapeutic Innovation and Regulatory Science, 2020, 54, 598-604.	0.8	3
43	Evaluating the Feasibility and Validity of a New Tool to Assess Organizational Preparedness and Capabilities to Support Patient Engagement in Drug Development. Therapeutic Innovation and Regulatory Science, 2021, 55, 1193-1198.	0.8	3
44	Public and patient usage and expectations for clinical trial registries. , 2006, , 47-58.		3
45	Trends driving clinical trials into large clinical care settings. Nature Reviews Drug Discovery, 2018, 17, 703-704.	21.5	3
46	Are Pharmacists a Viable Channel for Education about Clinical Trial Participation?. Drug Information Journal, 2011, 45, 443-453.	0.5	2
47	Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices. Drug Safety, 2015, 38, 687-692.	1.4	2
48	Analysis of Review Times for Recent 505(b)(2) Applications. Therapeutic Innovation and Regulatory Science, 2017, 51, 651-656.	0.8	2
49	Establishing Consensus Understanding of the Barriers to Drug Development in Lupus. Therapeutic Innovation and Regulatory Science, 2020, 54, 1159-1165.	0.8	2
50	US Physician and Nurse Proclivity to Refer Their Patients Into Clinical Trials. Therapeutic Innovation and Regulatory Science, 2020, 54, 404-410.	0.8	2
51	Benchmarking Patient Recruitment and Retention Practices. Therapeutic Innovation and Regulatory Science, 2021, 55, 19-32.	0.8	2
52	Benchmarking Protocol Deviations and Their Variation by Major Disease Categories. Therapeutic Innovation and Regulatory Science, 2022, 56, 632-636.	0.8	2
53	Unfulfilled translation opportunities in industry sponsored clinical trials. Contemporary Clinical Trials, 2013, 35, 80-86.	0.8	1
54	Communicating trial results to study volunteers: what does the future hold?. Clinical Investigation, 2014, 4, 777-779.	0.0	1

#	Article	IF	Citations
55	The Impact of Bad Protocols. , 2015, , 105-116.		1
56	Bridging the Academia/Industry Chasm: Proposed Solutions. Journal of Clinical Pharmacology, 2016, 56, 1457-1460.	1.0	1
57	Benchmarking the Vendor Qualification Process. Therapeutic Innovation and Regulatory Science, 2020, 54, 1349-1358.	0.8	1
58	The Promise and Progress of DIA 2011. Drug Information Journal, 2011, 45, 119-120.	0.5	0
59	Site Characteristics Influencing the Translation of Clinical Research Into Clinical Practice. Therapeutic Innovation and Regulatory Science, 2014, 48, 628-634.	0.8	0
60	Differences in Clinical Research Perceptions and Experiences by Age Subgroup. Therapeutic Innovation and Regulatory Science, 0, , 216847901881472.	0.8	0
61	US Physician and Nurse Proclivity to Refer Their Patients Into Clinical Trials. Therapeutic Innovation and Regulatory Science, 0, , 216847901983796.	0.8	0